INDOCO REMEDIES 2017-18 Annual Report Analysis

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES 2017-18 Annual Report Analysis
Thu, 28 Mar

INDOCO REMEDIES has announced its results for the year ended March 2018. Let us have a look at the detailed performance review of the company during FY17-18.

INDOCO REMEDIES Income Statement Analysis

  • Operating income during the year fell 3.1% on a year-on-year (YoY) basis.
  • The company's operating profit decreased by 13.8% YoY during the fiscal. Operating profit margins witnessed a fall and stood at 12.9% in FY18 as against 14.6% in FY17.
  • Depreciation charges increased by 7.0% and finance costs increased by 278.6% YoY, respectively.
  • Other income grew by 18.1% YoY.
  • Net profit for the year declined by 46.6% YoY.
  • Net profit margins during the year declined from 7.1% in FY17 to 3.9% in FY18.

INDOCO REMEDIES Income Statement 2017-18

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
Net SalesRs m10,74810,419-3.1%
Other incomeRs m404718.1%
Total RevenuesRs m10,78710,466-3.0%
Gross profitRs m1,5651,349-13.8%
DepreciationRs m6336777.0%
InterestRs m62235278.6%
Profit before taxRs m909484-46.8%
TaxRs m13972-47.8%
Profit after taxRs m771412-46.6%
Gross profit margin%14.612.9
Effective tax rate%15.315.0
Net profit margin%7.13.9
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



INDOCO REMEDIES Balance Sheet Analysis

  • The company's current liabilities during FY18 stood at Rs 4 billion as compared to Rs 4 billion in FY17, thereby witnessing an increase of 6.5%.
  • Long-term debt down at Rs 1 billion as compared to Rs 1 billion during FY17, a fall of 6.8%.
  • Current assets fell 6% and stood at Rs 5 billion, while fixed assets rose 18% and stood at Rs 6 billion in FY18.
  • Overall, the total assets and liabilities for FY18 stood at Rs 12 billion as against Rs 12 billion during FY17, thereby witnessing a growth of 3%.

INDOCO REMEDIES Balance Sheet as on March 2018

No. of Mths Year Ending12 Mar-17*12 Mar-18*% Change
NetworthRs m6,5136,7503.6
 
Current LiabilitiesRs m3,9044,1576.5
Long-term DebtRs m1,3231,233-6.8
Total LiabilitiesRs m11,96812,3633.3
 
Current assetsRs m5,7215,373-6.1
Fixed AssetsRs m 5,3076,24417.7
Total AssetsRs m11,96812,3633.3
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



INDOCO REMEDIES Cash Flow Statement Analysis

  • INDOCO REMEDIES's cash flow from operating activities (CFO) during FY18 stood at Rs 1 billion, an improvement of 38.4% on a YoY basis.
  • Cash flow from investing activities (CFI) during FY18 stood at Rs -1 billion on a YoY basis.
  • Cash flow from financial activities (CFF) during FY18 stood at Rs -388 million on a YoY basis.
  • Overall, net cash flows for the company during FY18 stood at Rs -521 million from the Rs 497 million net cash flows seen during FY17.

INDOCO REMEDIES Cash Flow Statement 2017-18

ParticularsNo. of months1212% Change
Year EndingMar-17Mar-18
Cash Flow from Operating ActivitiesRs m8861,22738.4%
Cash Flow from Investing ActivitiesRs m-1,706-1,360-
Cash Flow from Financing ActivitiesRs m1,316-388-
Net Cash FlowRs m497-521-
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Current Valuations for INDOCO REMEDIES

  • The trailing twelve-month earnings per share (EPS) of the company stands at Rs 4.5, an decline from the EPS of Rs 8.4 recorded last year.
  • The price to earnings (P/E) ratio, at the current price of Rs 187.6, stands at 286.7 times its trailing twelve months earnings.
  • The price to book value (P/BV) ratio at current price levels stands at 3.4 times, while the price to sales ratio stands at 2.2 times.
  • The company's price to cash flow (P/CF) ratio stood at 15.9 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Sales per share (Unadj.)Rs116.6113.1
TTM Earnings per shareRs8.44.5
Diluted earnings per shareRs8.44.5
Price to Cash Flow x12.315.9
TTM P/E ratiox286.6286.7
Price / Book Value ratiox4.33.4
Market CapRs m17,28317,287
Dividends per share (Unadj.)Rs1.61.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



Ratio Analysis for INDOCO REMEDIES

  • Solvency Ratios
  • Current Ratio: The company's current ratio deteriorated and stood at 1.3x during FY18, from 1.5x during FY17. The current ratio measures the company's ability to pay short-term and long-term obligations.

    Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at 3.1x during FY18, from 15.6x during FY17. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

  • Profitability Ratios
  • Return on Equity (ROE): The ROE for the company declined and down at 6.1% during FY18, from 11.8% during FY18. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

    Return on Capital Employed (ROCE): The ROCE for the company declined and down at 9.0% during FY18, from 12.4% during FY17. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

    Return on Assets (ROA): The ROA of the company declined and down at 5.2% during FY18, from 7.0% during FY17. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending12 Mar-17*12 Mar-18*
Current ratiox1.51.3
Debtors’ DaysDays7373
Interest coveragex15.63.1
Debt to equity ratiox0.20.2
Return on assets%7.05.2
Return on equity%11.86.1
Return on capital employed%12.49.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster



To see how INDOCO REMEDIES has performed over the last 5 years, please visit here.

INDOCO REMEDIES Share Price Performance

Over the last one year, INDOCO REMEDIES share price has moved up from Rs 210.8 to Rs 187.6, registering a loss of Rs 23.2 or around 11.0%.

(To know more, check out historical annual results for INDOCO REMEDIES and quarterly results for INDOCO REMEDIES)

Equitymaster requests your view! Post a comment on "INDOCO REMEDIES 2017-18 Annual Report Analysis". Click here!

  

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (3QFY20); Net Profit Up 74.9% (Quarterly Result Update)

Jan 27, 2020 | Updated on Jan 27, 2020

For the quarter ended December 2019, INDOCO REMEDIES has posted a net profit of Rs 93 m (up 74.9% YoY). Sales on the other hand came in at Rs 3 bn (up 10.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - CENTURY PLYBOARDS COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS